Skip to main content

Day: May 7, 2024

Jyske Realkredit A/S – Interim Financial Report, Q1 2024

Jyske Realkredit A/S – Interim Financial Report, Q1 2024 To NASDAQ Copenhagen A/S                                                                                                                  7 May 2024                                                                                                                 Announcement No. 41/2024 Interim Financial Report, Q1 2024 On May 7, 2024, the Supervisory Board has approved the Interim Financial Report, Q1 2024 of Jyske Realkredit A/S. Please see the attached file. Yours sincerely,Jyske Realkredit A/S Carsten Tirsbæk MadsenCEO Direct phone (+45) 89 89 90 50E-mail: ctm@jyskerealkredit.dk Web: jyskerealkredit.dk Please observe that the Danish version of this announcement prevails. Attached files:Interim Financial Report of Jyske Realkredit, Q1 2024.pdfAttachment...

Continue reading

Interim Financial Report, Q1 2024

Net interest income rose by 11% to DKK 2,462m (Q1 2023: DKK 2,224m) Core income was up by 4% to DKK 3,430m (Q1 2023: DKK 3,310m) Core expenses rose by 5% to DKK 1,557m (Q1 2023: DKK 1,480m) Loan impairment charges amounted to an expense of DKK 82m (Q1 2023: DKK 96m) Net profit was nearly unchanged at DKK 1,286m (Q1 2023: DKK 1,289m). Capital ratio at 22.0%, of which common equity tier 1 capital ratio at 16.6% (Q1 2023: 19.6% and 15.4%, respectively) Dividend of DKK 500m, corresponding to DKK 7.78 per share, adopted at the Annual General Meeting and paid out to the shareholders in March 2024 Share buy-back programme of up to DKK 1.5bn launches on 3 June.Summary ”Q1 2024 showed a net profit of DKK 1.3bn. This is in line with the highest results for the first quarter of the year so far due especially to the higher level of interest rates...

Continue reading

International Petroleum Corporation Announces First Quarter 2024 Financial and Operational Results

TORONTO, May 07, 2024 (GLOBE NEWSWIRE) — International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) today released its financial and operational results and related management’s discussion and analysis (MD&A) for the three months ended March 31, 2024. William Lundin, IPC’s President and Chief Executive Officer, comments: “We are pleased to announce another strong quarter of production and operational performance, which was combined with favourable commodity prices. IPC achieved an average net daily production during the quarter of 48,800 barrels of oil equivalent per day (boepd). Our financial results during the quarter are in line with the 2024 guidance announced at our Capital Markets Day in February as we continue to excel operationally across our operations in Canada, Malaysia and...

Continue reading

International Petroleum Corporation Announces First Quarter 2024 Financial and Operational Results

International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) today released its financial and operational results and related management’s discussion and analysis (MD&A) for the three months ended March 31, 2024. William Lundin, IPC’s President and Chief Executive Officer, comments: “We are pleased to announce another strong quarter of production and operational performance, which was combined with favourable commodity prices. IPC achieved an average net daily production during the quarter of 48,800 barrels of oil equivalent per day (boepd). Our financial results during the quarter are in line with the 2024 guidance announced at our Capital Markets Day in February as we continue to excel operationally across our operations in Canada, Malaysia and France. At the same time, we also continued with...

Continue reading

ABN AMRO completes EUR 500 million share buyback programme of 15 February 2024

ABN AMRO completes EUR 500 million share buyback programme of 15 February 2024 ABN AMRO today announced that it has completed its EUR 500 million share buyback programme which started on 15 February 2024. Under the share buyback programme a total of 32,526,813 ordinary shares and depository receipts were purchased, representing 3.76% of issued shares, at an average price of EUR 15.37. ABN AMRO intends to cancel the repurchased ordinary shares and corresponding depository receipts in due course. NLFI as a majority shareholder has participated pro-rata in the share buyback programme for 40% of the total program as NLFI is currently executing a trading program with the intention to bring down its stake to approximately 40%. Since the last update on the share buyback programme on 2 May 2024 a remaining number of 726,813 shares and depositary...

Continue reading

Rexel announces the acquisition of Talley

Rexel announces the acquisition of Talley, reinforcing its U.S. data communications offer Rexel has reached an agreement to acquire Talley, a leading distributor of wireless infrastructure products and solutions in the United States, strongly reinforcing its exposure to the fast-growing data usage trends. Talley provides network infrastructure products to mobile network operators, network installers, infrastructure operators and end-users across the US. Established in 1983 by the Talley family and headquartered in Los Angeles, Talley will generate turnover of c. $360m in 2024 and operates with the support of 11 warehouses and 300+ employees. This acquisition complements Rexel’s $700m sales in the datacom and datacenter spaces in North America. It enhances the group’s offer with both connected and electrified solutions to further benefit...

Continue reading

Coloplast A/S – Announcement no. 02/2024 – Interim Financial Report, H1 2023/24

H1 2023/24Interim financial results, H1 2023/241 October 2023 – 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin1) of 27%. Reported revenue in DKK grew 9% with 4%-points contribution from Kerecis (underlying growth of around 35%), partly offset by currencies.Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 8%) and Interventional Urology 5%. Continued good momentum in Chronic Care. Ostomy Care growth was driven by broad-based contribution from Emerging markets and Europe, compensating for lower growth in the US which was held back by order phasing and now expected to be H2 weighted. Continence Care growth was driven by intermittent catheters, including good contribution from LujaTM.   Voice...

Continue reading

Eezy Plc’s Interim Report 1–3/2024: Demand for staffing services remains weak – focus on increasing productivity

EEZY PLC —   INTERIM REPORT   — 7 MAY 2024 AT 8:00 Eezy Plc’s Interim Report 1–3/2024: Demand for staffing services remains weak – focus on increasing productivity January–March 2024Revenue was EUR 41.5 million (EUR 52.8 million in January–March 2023). Revenue decreased by 21%. EBITDA was EUR 2.3 million (3.4). EBIT was EUR 0.5 million (1.3) and was 1.2% of revenue (2.5%). EUR 0.3 million in personnel expenses related to severance payments were recorded in the result. Earnings per share was EUR 0.01 (0.02).Outlook for 2024 Eezy does not give guidance for 2024. Key figures (IFRS)EUR million, unless otherwise specified 1–3/2024 1–3/2023 1–12/2023Revenue 41.5 52.8 219.0EBITDA 2.3 3.4 14.5EBITDA, % 5.5% 6.5% 6.6%EBIT 0.5 1.3 4.0EBIT, % 1.2% 2.5% 1.8%EPS, basic, EUR 0.01 0.02 0.03EPS, diluted,...

Continue reading

Aspo Group Interim Report, January 1 – March 31, 2024: Successful strategy execution in a challenging operating environment

Aspo Plc Interim Report               May 7, 2024, at 8:00 am Aspo Group Interim Report, January 1 – March 31, 2024 Successful strategy execution in a challenging operating environment Figures from the corresponding period in 2023 are presented in brackets. January–March 2024Net sales from continuing operations decreased to EUR 132.7 (141.6) million. Comparable operating profit from continuing operations was EUR 4.8 (8.4) million, 3.6% (5.9%) of net sales. The comparable operating profit of ESL Shipping was EUR 2.7 (6.0) million, Telko EUR 2.2 (2.7) million, and Leipurin EUR 1.1 (1.0) million. Operating profit from continuing operations was EUR -3.2 (8.6) million, -2.4% (6.1%) of net sales. Operating profit of ESL Shipping was EUR -5.0 (6.0) million, Telko EUR 2.2 (2.7) million, and Leipurin EUR 1.1 (1.2) million. Items affecting...

Continue reading

Sandoz reports first quarter 2024 sales

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEStrong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in USD) Biosimilar business growing 21% in constant currencies  All regions contributing to growth Acquisition of CIMERLI® (ranibizumab-eqrn) completed in March 2024Basel, May 7, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced net sales for the first quarter 2024. Net sales were USD 2.5 billion, an increase of 6% in constant currencies compared to the same quarter of the prior year. Biosimilars saw another quarter of double-digit net sales growth, an increase of 21% in constant currencies. Generics sales remained in line with prior year levels. Richard Saynor, Chief Executive Officer...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.